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Abstract: This article describes the pharmacology of the novel atypical antidepressant drug 
agomelatine, critically reviews and evaluates its clinical use for the treatment of major depres-
sion, and suggests areas for further research. Agomelatine is a synthetic analog of the hormone 
melatonin. It stimulates the activity of melatonin MT1 and MT2 receptors and inhibits the activity 
of serotonin 5HT-2C receptor subtypes. Three acute trials demonstrated clinically modest, but 
statistically significant benefits over placebo. Three acute trials did not find agomelatine more 
effective than placebo. A meta-analysis of these six trials demonstrated a small, statistically 
significant, marginally clinically relevant difference between agomelatine and placebo. The 
only placebo-controlled study in elderly patients did not demonstrate a significant benefit for 
agomelatine. It was more effective than placebo in only one of two relapse prevention studies. 
Agomelatine was generally well tolerated compared to placebo. Its side-effect profile is different 
than and compares favorably to other antidepressant drugs. The overall tolerability of agomela-
tine in head-to-head comparisons was not substantially better than active drug comparators. 
Agomelatine is contraindicated in patients with impaired liver function and in patients taking 
drugs that potently inhibit CYP-1A2 metabolic enzymes. Because elevated liver enzymes are 
common, and there is a rare risk of more serious liver reactions, routine laboratory monitoring 
of liver function is recommended periodically throughout treatment. Agomelatine does not 
have clinically significant advantages compared to other antidepressant drugs, and it has cer-
tain limitations and disadvantages. Because of its unique pharmacology and relatively benign 
tolerability profile, however, it may be a useful alternative for patients who do not respond to 
or cannot tolerate other antidepressant drugs.
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Introduction
The goal of antidepressant drug therapy for major depression should be to achieve 
full remission, as demonstrated by the absence of significant depressive symptoms 
along with a complete recovery of social and vocational function.1 With any first-
choice antidepressant medication, about 50% to 70% of patients will have a signifi-
cant treatment response (usually defined as a 50% or greater decrease in depressive 
symptoms). Of these treatment responders, however, only about one-half to one-third 
attain a full remission. A significant proportion of depressed patients are therefore 
left with residual or persistent symptoms despite apparently adequate antidepressant 
therapy. The failure to achieve remission with antidepressant therapy is associated 
with an increased risk of relapse or recurrence, higher levels of impaired social 
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and vocational function, and a worse long-term prognosis. 
Chronic or recurrent depression is associated with persis-
tent social and vocational disability, an increased risk of 
suicide, greater medical morbidity and mortality, and higher 
health care utilization and costs.2–4 Patients with depressive 
symptoms less severe than major depression also suffer from 
significant impairment.5,6
Symptomatic improvement of depression can facilitate 
the process of functional recovery, thereby reducing dis-
ability, and this can help prevent possible complications 
related to the illness such as substance abuse and suicide.7 
Complications related to depression also extend to its effect 
on various medical conditions. Depression worsens the 
health outcome and functioning of patients with a variety 
of medical disorders.8 For example, heart disease, diabe-
tes, and osteoporosis are significantly worse in depressed 
compared to nondepressed patients.9–12 Having depression 
also contributes to poor treatment adherence for other medi-
cal conditions, and treating depression can improve medical 
adherence.13–16 Depression not only affects existing medical 
disorders, but can be associated with an increased risk of the 
later development of some medical conditions. Compared to 
nondepressed people, depressed patients are more likely to 
later develop heart disease, diabetes, and osteoporosis.10,17–19 
Depression also can adversely affect pregnancy outcome 
(eg, prematurity and low birthweight).20,21 Ineffectively or 
inadequately treating depression may therefore contrib-
ute to the substantial morbidity and mortality associated 
with many medical conditions as well as with depression 
itself.
Many types of antidepressant drugs are available, but 
their absolute effectiveness is limited.22 Many patients 
do not respond to available drugs, or they have residual 
symptoms despite adequate treatment. Some patients 
respond to medication, but they develop intolerable side 
effects and stop treatment. For these reasons, new drug 
therapies are always needed. Even though a new drug may 
not necessarily be more effective on average compared to 
available drugs, it might be relatively more efficacious or 
better tolerated for certain patients. In this paper, I will 
describe the pharmacology of the novel atypical antide-
pressant drug agomelatine, critically review and evaluate 
its clinical use for the treatment of major depression, and 
outline suggested areas for further research investigating 
this unique drug. The literature was reviewed for articles 
relating to agomelatine on MEDLINE, PsychINFO, and 
Google Scholar using the search terms “agomelatine” 
or “S-20098.” Additional literature potentially related to 
agomelatine was searched using the terms “melatonin,” 
“ramelteon,” or “TAK-375.”
Pharmacology and pharmacodynamic 
profile of agomelatine
After a drug is administered, it is eventually distributed 
to its site of action where it interacts with its particular 
targets. Pharmacodynamics refers to the pharmacological 
mechanism of action of a drug at its particular targets, 
which includes its therapeutic effects as well as any adverse 
effects. Psychotropic drug targets typically are various 
enzymes, transporters, and receptors that regulate the syn-
thesis, transmission, and degradation of different chemical 
neurotransmitters in the central nervous system. How a drug 
will affect patient function overall depends on the net effect 
of its intended therapeutic use together with any unintended 
effect on other organ systems throughout the body.23
Agomelatine has been extensively investigated in pre-
clinical studies.24 It also has been investigated in clinical 
trials in Europe for the treatment of depression and was 
first recommended for approval by the European Medicines 
Agency in November 2008.25–27 Clinical trials of agomelatine 
for depression (3 short-term efficacy and safety trials and 
1 longer-term relapse prevention trial) have been conducted 
in the United States, but the findings from these studies have 
not been released and it is not yet approved by the US Food 
and Drug Administration.28 Agomelatine is a synthetic analog 
of the hormone melatonin.29
Melatonin is secreted by the pineal gland and normally 
serves to regulate various circadian (24-hour) rhythms, 
including sleep–wake cycles. Disturbances in circadian 
rhythms have been implicated in the development of mood 
disorders as well as disrupted sleep patterns.30 Phase-shift 
hypotheses suggest that depression results from internal cir-
cadian rhythms that are phase delayed (or phase advanced in 
some patients) relative to external clock time (as exemplified 
by the light–dark cycle) and to sleep–wake cycles, resulting 
in a pathological desynchronization of ordinarily closely 
linked biological rhythms. The central internal (endogenous) 
circadian rhythm pacemaker (regulating such 24-hour bio-
logical cycles as endocrine function and body temperature) 
is located in the suprachiasmatic nucleus (SCN) of the 
hypothalamus.31 Light influences SCN function via a neural 
pathway from the retina to the SCN. A pathway from the 
SCN to the pineal gland regulates the synthesis and release 
of the melatonin. It is notable that melatonin is synthesized 
from the neurotransmitter serotonin.32 Melatonin secretion 
is regulated internally by the normal autonomous activity of 
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the SCN as well as externally by light exposure on the retina. 
Melatonin is effective for circadian rhythm sleep disturbances 
(eg, associated with jet lag), but it is only modestly effective 
in the treatment of insomnia unrelated to circadian rhythm 
sleep disturbances.33 It also does not appear to have inherent 
antidepressant effects.
Agomelatine is a potent melatonin-receptor agonist 
drug that strongly binds to and stimulates the activity of 
melatonin MT1 and MT2 receptors, which are localized 
within the SCN.34 Stimulation of MT1 and MT2 receptors 
has a normalizing effect on disturbed circadian rhythms 
and disrupted sleep–wake cycles. Agomelatine also is a 
serotonin-receptor antagonist that binds to and inhibits the 
activity of serotonin 5HT-2C receptor subtypes, but it does 
not bind to other serotonin receptor subtypes. 5HT-2C recep-
tor antagonism is associated with antidepressant and anti-
anxiety activity and also increases slow-wave sleep (which 
is abnormally diminished in depression).35 Agomelatine does 
not directly affect the uptake of serotonin, norepinephrine, 
or dopamine. By inhibiting 5HT-2C receptors, however, it 
secondarily increases norepinephrine and dopamine in the 
frontal cortex of the brain.36 This effect might contribute 
to its antidepressant activity. Agomelatine does not bind to 
adrenergic, cholinergic, or histamine receptors.
Ramelteon also is a synthetic analog of melatonin.29 It is 
a MT1 and MT2 receptor agonist drug currently approved 
in the United States, Europe, and elsewhere for the treat-
ment of insomnia characterized by difficulty falling sleep.34 
Unlike agomelatine, it does not bind to any serotonin recep-
tors and has not been investigated as an antidepressant.24 
Mirtazapine and some other antidepressant drugs have 
5HT-2C receptor blocking effects.37 Many of the so-called 
atypical or second generation antipsychotic drugs also have 
5HT-2C receptor blocking effects,37 and these drugs are 
efficacious as augmentation agents when used together with 
antidepressant drugs for treatment resistant depression.38 The 
pharmacology of agomelatine, with its combined effects at 
MT1, MT2, and 5HT-2C receptors, is therefore unique and 
distinct compared to other antidepressant drugs. Sleep EEG 
studies demonstrate the benefits of agomelatine on sleep in 
depressed patients (ie, increased slow-wave sleep and sleep 
efficiency).39 Increases in slow-wave sleep (the deepest stage 
of sleep) typically correlate with subjective daytime reports 
of having had a good night’s sleep and feeling well rested.40 
Agomelatine also has been shown to influence circadian 
rhythms in animals and humans.41–43 These effects are all 
consistent with what is expected based on its MT1, MT2, 
and 5HT-2C receptor pharmacology.
Stress-response systems are abnormally activated in 
depression, and the chemical effects of stress have damaging 
effects on nerve cells.44 In particular, persistent or exces-
sive levels of the glucocorticoid hormone cortisol45 or the 
excitatory amino acid glutamate,46 each of which has normal 
physiologic functions in the brain, can result in neurotoxic-
ity (nerve cell atrophy or death). Chronic stress can also 
result in decreased neurogenesis (nerve cell growth).47 Brain 
imaging studies show structural brain changes (eg, atrophy 
or enlarged ventricles) in patients with mood disorders, and 
this may partly reflect stress-induced neurotoxicity or the 
inhibition of neurogenesis.44,48 Many antidepressant drugs 
have the effect of reducing neurotoxicity or enhancing neu-
rogenesis.44 Similarly, agomelatine increases neurogenesis 
in the hippocampus region of the brain and may also have 
neuroprotective effects.49,50 The effects on neurogenesis and 
neurotoxicity are mediated in part by influencing glutamate 
release, glucocorticoid receptor gene expression, and various 
neurotrophic factors.51–55
Pharmacokinetic profile  
of agomelatine
Pharmacokinetics refers to the absorption, distribution, 
metabolism, and excretion of drugs in the body. After oral 
administration, agomelatine is rapidly and well absorbed 
from the gastrointestinal tract.56 Food tends to slow down 
the absorption of agomelatine, but this effect is not clini-
cally significant.
Regardless of the route of administration, all drugs will 
enter the systemic circulation and most will reversibly bind to 
various plasma proteins. Similar to most other psychotropic 
drugs, agomelatine is highly protein bound (its plasma 
protein binding is greater than 95%).57 Taking multiple 
drugs that bind to the same plasma protein sometimes 
can cause displacement of the protein-bound fraction of a 
drug, resulting in higher concentrations of the free fraction. 
Based on in vitro studies, agomelatine does not modify free 
concentrations of drugs highly bound to plasma proteins, nor 
do other drugs affect its protein binding.25 However, this has 
not been studied in vivo in humans.
Agomelatine is almost entirely metabolized through the 
liver, and it undergoes extensive first pass hepatic metabolism. 
One specific study investigated the influence of liver insuf-
ficiency in patients with hepatic cirrhosis on plasma levels 
of agomelatine.25 In patients with mild hepatic impairment, 
the increase in agomelatine exposure was more than 50 times 
higher compared with healthy subjects. For patients with 
moderate hepatic impairment, the exposure was more than 
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100 times higher compared with healthy subjects. In addition, 
because of decreases in plasma proteins, the unbound free 
fraction of agomelatine was increased in subjects with hepatic 
insufficiency. The free fraction was approximately twice as 
great in patients with moderate hepatic impairment.
The major cytochrome P-450 (CYP-450) enzyme 
involved in the metabolism of agomelatine is CYP-1A2 
(accounting for about 90% of its metabolism), with minor 
metabolic contributions by CYP-2C9 and CYP-2C19.24 
Agomelatine has at least four main metabolites. The phar-
macological activity of the metabolites for 5HT-2C, MT1, 
and MT2 receptors is not clearly established. None of the 
metabolites have any known toxic effects. Agomelatine does 
not appear to inhibit or induce the activity of any CYP-450 
enzymes in humans, but enzyme induction has been dem-
onstrated in animal studies.25
Agomelatine and its metabolites are mainly excreted 
through the kidneys. The elimination half-life of agomelatine 
is very short (about 2–3 hours). The effects of renal function 
on agomelatine pharmacokinetics were investigated in a 
study of healthy subjects and patients with severe impaired 
renal function.25 In the renal impairment patients, exposure to 
agomelatine increased more than 25% compared to healthy 
subjects.
In humans, the oral bioavailability of agomelatine at 
doses of 25 mg and 50 mg is very low. The bioavailability 
may increase at higher doses, perhaps due to saturation of 
first pass hepatic metabolism or due to nonlinear pharmaco-
kinetics. The oral bioavailability of agomelatine is estimated 
to be relatively higher in women compared to men and to 
be relatively higher in elderly versus younger individuals, 
perhaps due to gender and age effects on hepatic blood flow 
and metabolic enzyme activity.25 However, because of sig-
nificant intra-individual and inter-individual pharmacokinetic 
variability, dose changes based on age or gender are not 
considered to be routinely necessary. Also, bioavailability 
is relatively higher in nonsmokers versus smokers and 
in women taking estrogen-containing drugs compared to 
women who do not. These findings are explained by the 
metabolic enzyme-inducing effects of smoking and the 
enzyme-inhibiting effects of estrogens. Agomelatine does 
not affect the pharmacokinetics of the bronchodilator drug 
theophylline, which is a substrate for CYP-1A2. The selec-
tive serotonin reuptake inhibitor (SSRI) drug fluvoxamine is 
a potent inhibitor of CYP-1A2 and a moderate inhibitor of 
CYP-2C9, and it can significantly increase serum concentra-
tions of agomelatine. By contrast, the SSRI drug paroxetine is 
a moderate inhibitor of CYP-1A2 and does not significantly 
increase the concentration of agomelatine. The antifungal 
drug fluconazole is a potent inhibitor of CYP-2C9, but it 
has not been shown to significantly influence the pharma-
cokinetics of agomelatine. Specific drug-drug interaction 
studies involving lithium, lorazepam, alcohol, and valproic 
acid have not demonstrated any significant effects of these 
drugs on the pharmacokinetics of agomelatine.
Short-term clinical studies  
of agomelatine for major depression
The effectiveness of agomelatine for major depression has 
been investigated in 3 published58–60 and 3 unpublished25 
randomized, double-blind, placebo-controlled pivotal studies 
(see Table 1). Paroxetine or fluoxetine was included in some 
of these trials as an active comparison drug according to 
European regulatory guidelines. For each of the pivotal stud-
ies, the 17-item Hamilton Depression Rating Scale (HDRS) 
was the primary outcome measure. The primary outcome 
efficacy variable was the HDRS score for agomelatine versus 
placebo at endpoint. Response and remission rates based on 
the HDRS were considered secondary outcome variables. 
Response was defined as a 50% decrease in the HDRS score 
at endpoint. Remission was defined as a HDRS score of 6 
or less at endpoint.
In an 8-week dose-finding study involving 711 patients 
(18–65 years old), Loo and colleagues58 compared 3 doses of 
agomelatine (1, 5, and 25 mg/day), placebo, and paroxetine 
20 mg/day (as an active comparison). Agomelatine 25 mg 
(but not the 2 lower doses) and paroxetine were significantly 
more effective than placebo. The mean difference in HDRS 
was 2.57 for agomelatine (25 mg) versus placebo (P = 0.034) 
and 2.25 for paroxetine versus placebo (P = 0.030). Response 
rates for agomelatine 1 mg (62.5%) and 25 mg (61.5%) were 
significantly better than for placebo (46.3%), but agomelatine 
5 mg (51.4%) and paroxetine (56.3%) were not significantly 
higher than placebo. Remission rates for agomelatine 25 mg 
(30.4%) and paroxetine (25.7%) were significantly greater 
than for placebo (15.4%), but the rates for agomelatine 1 mg 
(21.3%) and 5 mg (17.8%) were not significantly better than 
placebo. The overall rate of treatment-emergent adverse 
events (TEAEs) was similar for agomelatine (51%) and 
placebo (55%), but slightly higher for paroxetine (66%). 
Most adverse events were experienced as mild to moderate in 
severity. There was no significant difference in drop-out rates 
due to TEAEs between agomelatine, placebo, and paroxetine. 
Reported side effects of headache, anxiety, abdominal pain, 
diarrhea, nausea, somnolence, insomnia, rhinitis, and dry 
mouth were no different between agomelatine and placebo, 
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but nausea was significantly more common with paroxetine 
compared to placebo and agomelatine. There were no sig-
nificant differences among the groups with respect to weight 
changes, cardiovascular effects, or laboratory studies.
In a second 6-week study involving 212 patients 
(18–65 years old), Kennedy and Emsley59 compared 
agomelatine 25 to 50 mg/day and placebo. After an initial 
2-week treatment with agomelatine 25 mg/day or placebo, 
the study medication dosage of patients with poor response 
was increased under double-blind conditions to agomelatine 
50 mg/day or matching placebo. Among the 106 patients 
taking agomelatine, 69 patients stayed at 25 mg/day and 
36 patients increased to 50 mg/day. Agomelatine (both doses 
pooled) was significantly more effective than placebo. The 
mean difference in HDRS was 2.30 for agomelatine versus 
placebo (P = 0.026). Response rates for agomelatine (49.1%) 
and placebo (34.3%) were significantly different, but remission 
rates for agomelatine (20.8%) and placebo (13.3%) were not 
significantly different. The overall rate of TEAEs was similar 
for agomelatine (30%) and placebo (36%). Most TEAEs were 
mild to moderate in severity. Drop-out rates due to TEAEs 
were similar for placebo (4.8%) and agomelatine (4.7%). 
Dizziness and rhinitis were more common with agomelatine 
compared to placebo, whereas headache, nausea, fatigue, 
dry mouth, and diarrhea were more common with placebo 
compared to agomelatine. There were no differences between 
agomelatine and placebo with respect to weight changes, 
cardiovascular effects, or laboratory studies.
In a third 6-week study involving 238 patients (18–65 years 
old), Olie and Kasper60 compared agomelatine 25 to 50 mg/day 
and placebo. If patients did not respond adequately after 
2 weeks of agomelatine 25 mg/day or placebo, the dosage 
was increased under double-blind conditions to 50 mg/day or 
matching placebo. Among the 118 patients on agomelatine, 
82 stayed at 25 mg/day and 29 increased to 50 mg/day. 
Agomelatine (both doses pooled) was significantly more 
effective than placebo. The mean difference in HDRS 
was 3.18 for agomelatine versus placebo (P = 0.002). 
Table 1 Summary of randomized controlled clinical efficacy studies of agomelatine
Study (Reference) Design Comparison Study outcome
Loo et al58 Efficacy and safety  
8 weeks  
711 subjects
AGO 1 mg  
AGO 5 mg  
AGO 25 mg  
PBO  
PAr 20 mg
AGO 1 mg = PBO  
AGO 5 mg = PBO  
AGO 25 mg  PBO  
PAr  PBO
Kennedy and emsley59 Efficacy and safety  
6 weeks  
212 subjects
AGO 25–50 mg  
PBO
AGO  PBO
Olie and Kasper60 Efficacy and safety  
6 weeks  
238 subjects
AGO 25–50 mg  
PBO
AGO  PBO
CL3-02225 Efficacy and safety  
6 weeks  
419 subjects
AGO 25 mg  
PBO  
FLx 20 mg
AGO = PBO  
FLx  PBO
CL3-02325 Efficacy and safety  
6 weeks  
418 subjects
AGO 25 mg  
PBO  
PAr 20 mg
AGO = PBO  
PAr = PBO
CL3-02425 Efficacy and safety  
6 weeks  
607 subjects
AGO 25 mg  
AGO 50 mg  
PBO  
FLx 20 mg
AGO = PBO  
FLx = PBO
CL3-02625 Efficacy and safety in elderly  
6 weeks  
218 subjects
AGO 25 mg  
PBO
AGO = PBO
Goodwin et al61 relapse prevention  
34 weeks  
339 subjects
AGO 25–50 mg  
PBO
AGO  PBO
CL3-02125 relapse prevention  
34 weeks  
367 subjects
AGO 25 mg  
PBO
AGO = PBO
Notes:  denotes significantly better than; = denotes no significant difference. 
Abbreviations: AGO, agomelatine; PBO, placebo; PAR, paroxetine; FLX, fluoxetine.
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Response rates for agomelatine (54.3%) and placebo 
(35.3%) were significantly different, but remission rates for 
agomelatine (17.2%) and placebo (11.8%) were not sig-
nificantly different. The overall rate of TEAEs was similar 
for agomelatine (42%) and placebo (43%). Most TEAEs 
were mildly to moderately severe. Drop-out rates due to 
TEAEs were slightly higher for placebo (5.8%) compared 
to agomelatine (3.4%). Fatigue, nausea, dizziness, rhinitis, 
and dry mouth were no different between agomelatine and 
placebo, but headache was significantly more common with 
placebo compared to agomelatine. Sexual functioning, weight 
changes, cardiovascular effects, and laboratory studies did 
not differ between groups.
In a 6-week unpublished study (study CL3-022)25 involv-
ing 419 patients (18–60 years old), the investigators com-
pared agomelatine 25 mg/day, placebo, and the SSRI drug 
fluoxetine 20 mg/day (as an active comparison). Agomelatine 
was not significantly more effective than placebo (the 
mean difference in HDRS was 1.4 for agomelatine versus 
placebo). Response rates for agomelatine (53%) and placebo 
(47%) were not significantly different. Remission rates for 
agomelatine and placebo also were not significantly different 
(actual rates were not reported). By contrast, fluoxetine was 
significantly more effective than placebo (the mean difference 
in HDRS was 2.59 for fluoxetine versus placebo). Response 
and remission rates for fluoxetine were not reported. There 
was no significant difference in drop-out rates due to TEAEs 
during the 6-week trial between agomelatine, placebo, and 
fluoxetine. At the end of 6 weeks, subjects responding to 
agomelatine or to fluoxetine were eligible for an 18-week 
double-blind placebo-controlled extension phase. Among 
these subjects, the final depression score was lower in 
the agomelatine group than in the placebo group, but the 
difference was not statistically significant. Nine subjects 
in the agomelatine group (14.3%), 20 in the placebo group 
(33.3%), and 13 in the fluoxetine group (17.8%) relapsed 
during the continuation phase. The survival curve time to 
relapse analysis showed a statistically significant difference 
favoring active drug (agomelatine or fluoxetine) compared 
to placebo.
In another 6-week unpublished study (study CL3-023)25 
involving 418 patients (18–60 years old), the investigators 
compared agomelatine 25 mg/day, placebo, and paroxetine 
20 mg/day (as an active comparison). Agomelatine was not 
significantly more effective than placebo (the mean difference 
in HDRS was 0.8 for agomelatine versus placebo). Response 
and remission rates for agomelatine and placebo were not 
significantly different (actual rates were not reported). 
Paroxetine was not significantly more effective than placebo 
(the mean difference in HDRS was 1.6 for paroxetine versus 
placebo). Response and remission rates for paroxetine were 
not reported. During the acute 6-week trial, there was no 
significant difference in drop-out rates due to TEAEs between 
agomelatine, placebo, and paroxetine. At the end of 6 weeks, 
subjects responding to agomelatine or to paroxetine were 
eligible for an 18-week, double-blind, placebo-controlled 
extension phase. There were no significant differences 
in outcome between active drugs or placebo in the extension 
phase. Drop-out rates due to TEAEs during the extension 
phase were similar for agomelatine (3.3%) and placebo 
(3.4%), but higher for paroxetine (8.6%).
In the last 6-week unpublished study (study CL3-024)25 
involving 607 patients (18–65 years old), the investiga-
tors compared two doses of agomelatine (25 mg/day and 
50 mg/day), placebo, and fluoxetine 20 mg/day (as an active 
comparison). Agomelatine 25 mg was not significantly more 
effective than placebo (the mean difference in HDRS was 1.4 
for agomelatine versus placebo). Agomelatine 50 mg also 
was not significantly more effective than placebo (HDRS 
data were not reported). Similarly, fluoxetine was not signifi-
cantly more effective than placebo (the mean difference in 
HDRS was 0.53 for fluoxetine versus placebo). Response and 
remission rates for agomelatine and for fluoxetine were not 
reported. At the end of 6 weeks, subjects responding to 
agomelatine or to fluoxetine were eligible for an 18-week, 
double-blind, placebo-controlled extension phase. In this 
phase, there were no significant differences in outcome 
between active drugs or placebo. Throughout the acute and 
extension phases of the study, there was no significant differ-
ence in drop-out rates due to TEAEs between agomelatine, 
placebo, and fluoxetine.
In addition to the six pivotal studies, a 6-week unpublished 
study (study CL3-026)25 involving 218 elderly patients 
(60 years and older) was conducted comparing agomelatine 
25 mg/day and placebo (see Table 1). For this study, the 
Montgomery Asberg Depression Rating Scale (MADRS) was 
the primary outcome measure. The primary outcome efficacy 
variable was the MADRS score for agomelatine versus pla-
cebo at endpoint. The response rate based on the MADRS 
was considered a secondary outcome variable. Response was 
defined as a 50% decrease in the MADRS score at endpoint. 
Remission rates were not reported in this study. Agomelatine 
was not significantly more effective than placebo (the mean 
difference in MADRS was 0.19 for agomelatine versus 
placebo). Response rates for agomelatine (46%) and placebo 
(52%) were not significantly different. At the end of 6 weeks, 
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subjects responding to acute treatment were eligible for an 
18-week, double-blind, placebo-controlled extension phase. 
There were no significant differences in outcome between 
active drugs or placebo during the extension phase. In an 
unplanned post-hoc subgroup analysis of data from this study, 
agomelatine was significantly more effective than placebo 
among the subgroup of 86 patients with more severe levels 
of depression. In a post-hoc pooled analysis of data from the 
3 published short-term pivotal studies,58–60 which included 
subjects over 60 years of age, a significant antidepressant 
effect was observed in the subgroup of 53 patients who were 
60–66 years old.
The efficacy of agomelatine for children and adolescents 
(younger than 18 years) having major depression has not 
been investigated.
Longer-term relapse prevention 
studies of agomelatine for major 
depression
The effectiveness of agomelatine has been investigated in 
1 published and 1 unpublished longer-term, randomized, 
double-blind, placebo-controlled relapse prevention study 
in patients with recurrent major depression (see Table 1). In 
both studies, subjects were eligible for the randomized phase 
if they had a response (50% reduction in HDRS) or a remis-
sion (HDRS less than seven) after acute open-label treatment 
with agomelatine. In both studies, relapse was defined as one 
of the following: a HDRS score greater than 15, withdrawal 
for lack of efficacy, suicide, or suicide attempt.
In a trial reported by Goodwin and colleagues,61 
492 patients (19–65 years old) were initially treated openly 
with agomelatine 25 to 50 mg/day for up to 10 weeks. 
After 2 weeks of agomelatine 25 mg/day, the dosage for poor 
responders was increased to 50 mg/day. The 339 patients 
who were responders or remitters were then randomized to 
receive double-blind treatment with agomelatine (at their 
current dose) or placebo for up to 24 weeks until they 
suffered a relapse. At the time of randomization, 22% of 
subjects were taking 50 mg/day and the remaining patients 
were taking 25 mg/day. Among all patients, 70% taking 
agomelatine completed the 24-week study compared to only 
52% taking placebo. Overall, agomelatine patients had a 
significantly lower cumulative relapse rate (22%) compared 
to placebo patients (47%). In a post-hoc data analysis, the 
cumulative relapse rate for agomelatine-treated patients 
(22%) was significantly lower than the rate for placebo-
treated patients (45%) among the subgroup of patients with 
more severe levels of depression. The overall rate of TEAEs 
was similar for agomelatine (56%) and placebo (56%). 
The most common TEAEs were headache (agomelatine 
10.3%; placebo 7.5 %), rhinitis (agomelatine 6.7%; placebo 
9.8%), and back pain (agomelatine 6.1%; placebo 3.4%). 
Agomelatine was not associated with significant effects 
on sexual functioning, weight, cardiovascular effects, or 
laboratory studies.
In the unpublished trial (study CL3-021),25 551 patients 
(19–67 years old) were initially treated openly with 
agomelatine 25 mg/day for up to 8 weeks. The 367 patients 
who were responders or remitters were then randomized to 
receive double-blind treatment with agomelatine or placebo 
for up to 34 weeks until they suffered a relapse. Overall, 
agomelatine-treated patients had a similar cumulative 
relapse rate (26%) compared to placebo-treated patients 
(24%). In a post-hoc data analysis, the cumulative relapse 
rate for agomelatine-treated patients (21%) was significantly 
lower than the rate for placebo-treated patients (31%) 
among the subgroup of patients with more severe levels 
of depression.
Tolerability and safety  
of agomelatine in placebo-
controlled pivotal trials
The tolerability and safety of agomelatine has been assessed 
extensively in the six short-term pivotal studies.25 These 
studies included 1120 patients taking agomelatine 25 to 
50 mg/day, 998 patients taking placebo, 284 patients taking 
fluoxetine 20 mg/day, and 283 patients taking paroxetine 
20 mg/day. The overall rate of TEAEs was similar for 
agomelatine (53%), placebo (52%), and fluoxetine (49%), 
but slightly higher for paroxetine (68%). The most commonly 
reported adverse events for agomelatine (in descending 
order of their incidence) were headache, nausea, dizziness, 
dry mouth, diarrhea, somnolence, fatigue, upper abdominal 
pain, and anxiety. Each of these adverse events was reported 
in less than 15% of patients. The incidence of adverse events 
was slightly higher for the 50 mg dose compared to the 
25 mg dose. Most agomelatine adverse events were mildly 
to moderately severe. The only adverse events significantly 
higher for agomelatine compared to placebo were dizziness, 
paresthesias, and blurred vision. The most commonly reported 
adverse events for the two SSRI drugs (in descending order of 
their incidence) were nausea, headache, dry mouth, diarrhea, 
somnolence, fatigue, insomnia, dizziness, and anxiety. Each 
of these was reported in less than 16% of patients. The largest 
 Neuropsychiatric Disease and Treatment 2009:5570
Howland Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
difference between agomelatine and the SSRI drugs in the 
incidence of any adverse event was for nausea, which favored 
agomelatine.
In addition to the two relapse prevention studies, many 
of the short-term pivotal studies had optional extension 
phases. Based on data collected from the relapse preven-
tion and extension phase studies altogether, longer-term 
tolerability and safety of agomelatine has been assessed for 
up to 24 weeks.25 These data include 511 patients taking 
agomelatine 25 to 50 mg/day, 406 patients taking placebo, 
222 patients taking fluoxetine 20 mg/day, and 105 patients 
taking paroxetine 20 mg/day. The overall rate of TEAEs 
was similar for agomelatine (39%) and placebo (38%), 
but slightly lower for fluoxetine (32%) and slightly higher 
for paroxetine (45%). The rate of TEAEs was higher for 
agomelatine 50 mg/day (48%) than for 25 mg/day (36%). 
The most commonly reported adverse events for agomelatine 
(in descending order of their incidence) were headache, back 
pain, and insomnia, each of which was reported in less than 
10% of patients. The only adverse event that was significantly 
higher for agomelatine compared to placebo was insomnia. 
The most commonly reported adverse events for the 2 SSRI 
drugs (in descending order of their incidence) were head-
ache, diarrhea, insomnia, and anxiety. Each of these was 
reported in less than 9% of patients. There were no major 
differences in long-term tolerability between the SSRI drugs 
and agomelatine.
A limited number of patients (400) took agomelatine 
for 1 year.25 There were few TEAEs during this extended 
time (each occurring in fewer than 3% of patients), and 
none were different than what was seen in the short-term 
and long-term studies. No comparisons were available with 
placebo or SSRI drugs.
Among all patients enrolled in clinical studies, there was 
no significant difference in the overall rate of serious adverse 
events for agomelatine 25 mg/day (4.1%) and 50 mg/day 
(4.4%), compared to placebo (4.1%). The most common seri-
ous adverse events were suicide attempts (agomelatine 0.6% 
versus placebo 0.4%), depression (agomelatine 0.5% versus 
placebo 0.8%), and falls (agomelatine 0.3% versus placebo 
0.3%). In the depression trials, deaths (all but 1 due to suicide) 
were reported in four of 3956 patients taking agomelatine 
(0.1%), 1 of 826 patients taking placebo (0.1%), and three 
of 449 patients taking paroxetine (0.7%). In nondepression 
clinical trials, the percentage of deaths among patients taking 
agomelatine (16 of 782 patients; 2%) was higher than for 
patients taking placebo (one of 327 patients; 0.3%). Fifteen 
of the 16 deaths in agomelatine-treated patients occurred in a 
study of 356 elderly patients who had Alzheimer’s dementia 
(a mortality rate of 4.2%).
In the clinical trials, significant elevations of liver 
enzymes (ie, increases greater than three times the upper 
limit of normal) occurred in 1.39% of patients taking 
agomelatine 50 mg/day, 1.04% taking 25 mg/day, and 0.72% 
taking placebo.25 These liver reactions occurred at various 
times throughout the 6-month observation period of these 
studies. They were detected in patients only through labora-
tory monitoring, because they did not have obvious clinical 
signs or symptoms indicating liver injury. Some reactions 
recovered during continued treatment and some recovered 
after treatment discontinuation. Serious liver reactions, 
including hepatitis and enzyme elevations greater than ten 
times the upper limit of normal, were reported less frequently. 
One patient developed hepatitis that did not recover at 
follow-up (2.5 years after discontinuation of agomelatine). 
These reactions in humans are not inconsistent with the find-
ings from animal studies. Repeated dose toxicity studies in 
rats and monkeys have indicated that the liver is the target 
organ of toxicity. Agomelatine causes hepatic enzyme induc-
tion in these animals, and they consequently showed enlarged 
livers or hepatocellular hypertrophy.
As described in the section on pharmacokinetics, liver 
insufficiency results in a significant increase in the exposure 
to agomelatine. Because the safety of such large concentra-
tions of agomelatine is unknown, it should not be used in 
patients with hepatic insufficiency, such as cirrhosis or other 
active liver disease.
Agomelatine does not significantly affect renal function. 
In patients with normal hepatic function, impaired renal 
function would be expected to result in greater exposure 
to agomelatine metabolites rather than to parent drug. The 
available safety data from the clinical trials did not demon-
strate any significant tolerability or safety issues with the 
use of agomelatine compared to placebo among patients 
with mildly to moderately impaired renal function. However, 
experience in patients with more severe renal impairment 
is unknown. Although agomelatine can be used in patients 
with renal impairment, such patients should be monitored 
more closely.
Agomelatine has not been associated with significant 
weight gain or adverse metabolic effects. Only 4 of 
400 patients taking it for one year gained weight. It does not 
have adverse cardiac effects (eg, electrocardiogram or blood 
pressure changes). With the exception of potential adverse 
liver effects, animal and human studies have not identified 
significant toxicity, even with excessively high doses.
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Among patients older than 65 years, safety data are 
available on 109 patients taking agomelatine and 76 taking 
placebo.25 Rates of TEAEs were similar for agomelatine 
(63.3%) and placebo (59.2%). Discontinuation rates due to 
TEAEs were 12.8% for agomelatine and 9.2% for placebo. 
Serious adverse events occurred in 4.6% of patients taking 
agomelatine and in 5.2% taking placebo.
Tolerability and safety of agomelatine 
in nonpivotal clinical trials
In addition to the randomized placebo-controlled pivotal 
studies, data on the tolerability and efficacy of agomelatine 
have been investigated in several other clinical trials.
In a 12-week randomized double-blind study involv-
ing 276 male and female patients with depression (18–60 
years old), Kennedy and colleagues62 compared agomela-
tine (50 mg/day) and the serotonin-norepinephrine reupake 
inhibitor (SNRI) antidepressant venlafaxine (titrated from 
75 mg/day to 150 mg/day after 2 weeks). The primary objec-
tive of this study was to compare the sexual effects of these 
2 drugs using data taken from the Sex Effects Scale. On the 
primary outcome measure of sexual function, there was a 
numerical advantage favoring agomelatine over venlafaxine, 
but these results were not statistically significant. Only several 
of the secondary outcome measures of sexual function showed 
statistically significant differences in favor of agomelatine. 
The overall rate of TEAEs for agomelatine (20%) was lower 
than for venlafaxine (38%). The most commonly reported 
adverse events were nausea (agomelatine 11.7% versus ven-
lafaxine 17.3%) and headache (agomelatine 10.2% versus 
venlafaxine 7.9%). Discontinuation rates due to TEAEs were 
2.2% for agomelatine and 8.6% for venlafaxine. There was no 
difference in antidepressant efficacy between the two drugs.
The objective of another study was to compare the 
sexual effects of agomelatine and paroxetine in healthy 
nondepressed male subjects.63 In this 8-week double-blind 
study, 92 subjects (18–30 years old) were randomized to 
1 of 2 doses of agomelatine (25 or 50 mg/day), placebo, or 
paroxetine (20 mg/day). On the primary and secondary out-
come measures of sexual function (using data taken from the 
Psychotropic-Related Sexual Dysfunction Questionnaire), 
agomelatine (at both doses) and placebo were not signifi-
cantly different. These three groups were significantly less 
impaired than the paroxetine-treated group.
In a 6-week randomized double-blind study involv-
ing 332 male and female depressed patients (18–65 years 
old), Lemoine and colleagues64 compared agomelatine 
(25–50 mg/day) and venlafaxine (75–150 mg/day). 
The primary objective of this study was to compare the 
sleep effects of these two drugs using the Leeds Sleep 
Evaluation Questionnaire. On the primary outcome measure 
of sleep, and on most of the secondary outcome measures, 
there was a clinically modest, but statistically significant 
advantage favoring agomelatine over venlafaxine. The 
overall rate of TEAEs was slightly lower for agomelatine 
(52%) compared to venlafaxine (57%). The most commonly 
reported adverse events (agomelatine versus venlafaxine, 
respectively) were nausea (6.0% versus 22.6%), headache 
(9.6% versus 11.9%), dizziness (1.8% versus 9.5%), vomit-
ing (1.2% versus 4.8%), diarrhea (4.8% versus 1.8%), and 
somnolence (3.6% versus 4.8%). Rates of discontinuation 
due to TEAEs were 4.2% for agomelatine and 13.2% for 
venlafaxine. There was no difference in antidepressant 
efficacy between the 2 drugs.
Another 6-week randomized double-blind study whose 
primary objective was to compare agomelatine (25–50 mg/day) 
and the SSRI drug sertraline (50–100 mg/day) on the 
rest–activity cycle of depressed patients has been completed. 
Neither the results based on the primary outcome measure 
nor other tolerability and safety data have been reported.65 
As a pre-specified secondary outcome, antidepressant effi-
cacy was assessed. Although complete details of this study 
have not been published,66 the data submitted to the Euro-
pean Medicines Agency demonstrated a small statistically 
significant treatment effect of 1.68 on the HDRS in favor of 
agomelatine over sertraline.25
The effects of abruptly discontinuing agomelatine 
and paroxetine have been compared in a randomized, 
double-blind, placebo-controlled study.67 After 12 weeks 
of double-blind treatment with agomelatine 25 mg/day or 
paroxetine 20 mg/day, 192 depressed patients who were in 
sustained remission were randomized to continue taking 
their current drug or to switch to placebo for 2 weeks. 
Discontinuation symptoms (rated on the Discontinuation 
Emergent Signs and Symptoms checklist) were significantly 
higher in the paroxetine-discontinuation group during the 
first week of placebo, but not during the second week. 
Discontinuation symptoms were not observed in the 
agomelatine-discontinuation group during the first or second 
week of placebo.
In a 12-week randomized, double-blind, placebo-
controlled study involving 121 male and female patients 
with generalized anxiety disorder (18–65 years old), Stein 
and colleagues68 compared agomelatine (25–50 mg/day) 
and placebo. If patients did not respond adequately after 
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2 weeks of agomelatine 25 mg/day or placebo, the dosage 
was increased under double-blind conditions to 50 mg/day 
or matching placebo. Agomelatine was significantly more 
effective than placebo on the primary outcome measure of 
anxiety (total score on the Hamilton Anxiety Rating Scale). 
The overall rate of TEAEs was similar for agomelatine 25 mg 
(36.1%), 50 mg (38.5%), and placebo (34.5%). The most 
common TEAEs that were reported more frequently in the 
agomelatine than in the placebo groups were dizziness (7.9% 
versus 3.4%) and nausea (4.8% versus 1.7%). Most TEAEs 
were mildly to moderately severe. Drop-out rates due to 
TEAEs were slightly lower for placebo (none) compared to 
agomelatine (1.6%). Cardiovascular effects and laboratory 
studies did not differ between groups.
Tolerability and safety of agomelatine 
in overdoses, pregnancy,  
and pediatric populations
There is limited clinical experience with agomelatine 
overdose in humans. Reported overdoses with agomelatine 
(up to 525 mg) have not resulted in significant or serious 
sequelae. It should also be noted that in the earliest clinical 
studies, healthy subjects took agomelatine doses as high 
as 1200 mg and the maximum tolerated dose was 800 mg. 
In animals, the LD50 dose is at least 100 times greater than 
the comparable human dose. Hence, the acute toxic effects 
of agomelatine have a relatively favorable safety profile.
There are no specific data on the safety of agomelatine 
during pregnancy or with breast feeding. Two phase I 
studies (1 in men, 1 in women) did not demonstrate any 
adverse effect of agomelatine on various gonadotrophic 
hormones, spermogram, or menstrual cycle. Reproduction 
toxicity studies in animals did not reveal any adverse 
effect of agomelatine on fertility or on embryonal or fetal 
development.
A small open-label sleep study in 9 pediatric patients 
(6–17 years old) with Smith-Magenis syndrome reported that 
agomelatine was well tolerated.69 The tolerability and safety 
of agomelatine has not otherwise been studied in children 
and adolescents.
Clinical considerations on the  
use of agomelatine and areas  
for further study
The antidepressant eff icacy of agomelatine has been 
systematically assessed in 6 short-term acute studies and 
2 longer-term relapse prevention studies. Three acute trials 
demonstrated clinically modest, but statistically significant 
benefits over placebo. Three acute trials did not find agomela-
tine to be more effective than placebo. Low-dose fluoxetine 
was more effective than placebo in one of these negative trials. 
Low-dose fluoxetine and low-dose paroxetine were not more 
effective than placebo in the other 2 negative trials. The lack 
of efficacy of the active comparator drugs in these 2 trials was 
believed mainly to be due to an insufficient dose and possibly 
to unusually high placebo responder rates.25
The only controlled study conducted in elderly patients 
did not demonstrate a significant benefit for agomelatine 
compared to placebo. Agomelatine was more effective 
than placebo in only 1 of the 2 relapse prevention studies. 
A meta-analysis of the 6 acute trials submitted to the 
European Medicines Agency demonstrated a small statisti-
cally significant treatment effect of about 1.5 on the HDRS 
in favor of agomelatine over placebo.25 The results from 
these studies suggest that agomelatine 25 mg/day is prob-
ably less effective than other antidepressant drugs. In their 
summary in approving agomelatine, the European Medicines 
Agency concluded that some positive treatment effect of 
agomelatine in major depression was demonstrated, but that 
the magnitude of effect was considered to be of marginal 
clinical relevance.25
In these clinical trials, agomelatine was generally well 
tolerated compared to placebo. The most common side effects 
associated with agomelatine are headache, nausea, dizziness, 
dry mouth, diarrhea, somnolence, fatigue, upper abdominal 
pain, and anxiety. The relatively benign side effect profile 
of agomelatine (especially the lack of clinically significant 
weight gain, the low risk of sexual dysfunction, the low 
incidence of gastrointestinal symptoms, and the absence of 
discontinuation symptoms) is different than and compares 
favorably to SSRI and SNRI drugs. However, the overall 
tolerability of agomelatine in head-to-head comparisons 
was not substantially better than active drug comparitors, 
as evidenced by the roughly similar rates of discontinuation 
due to TEAEs.
One particular concern with the use of agomelatine is 
liver function. Significant elevations of liver enzymes are 
common. These were sometimes very serious and included 
rare cases of hepatitis. Because these hepatic reactions were 
not predictable based on clinical symptoms or the duration 
of treatment, monitoring of liver enzyme levels of all patients 
has been recommended before starting treatment, after 6, 12, 
and 24 weeks of treatment, and then thereafter when clinically 
indicated based on the judgment of the treating physician. 
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“Real world” patients in general practice are likely to be quite 
different than the patients enrolled in clinical trials.70 As a 
result, the relative safety of agomelatine is unknown when 
used in patients who might have undetected liver impairment 
or liver disease or in patients who are at risk for developing 
liver disease. Commonly encountered clinical scenarios, for 
example, would include treating depressed patients at risk 
for developing viral hepatitis and treating patients who use 
alcohol, acetaminophen, or other prescription and nonpre-
scription drugs that affect the liver. Also, pharmacokinetic 
studies indicate that even mild hepatic insufficiency results in 
very elevated concentrations of agomelatine. For this reason, 
agomelatine is contraindicated in patients with any degree 
of liver impairment, such as cirrhosis or other active liver 
disease. All of these issues regarding the liver are of obvious 
concern for the routine use of agomelatine. The liver precau-
tions and the need for laboratory monitoring are a distinct 
disadvantage for the use of agomelatine compared to many 
other antidepressant drugs.
Agomelatine is metabolized primarily by CYP-1A2 
enzyme in the liver, with lesser metabolic contributions from 
CYP-2C9/2C19. Based on this, the use of agomelatine is 
contraindicated in patients taking drugs strongly inhibiting 
this enzyme (eg, fluvoxamine). Moderate inhibitors of 
CYP-1A2, such as estrogen-containing oral contraceptives 
and paroxetine, increase agomelatine concentrations to a 
lesser degree. Patients taking any drugs having moderate 
inhibitory effects on CYP-1A2 or drugs having inhibitory 
effects on CYP-2C9/2C19 should simply be monitored for 
increased adverse effects. It is possible that patients taking 
one or more drugs that have moderate metabolic enzyme 
inhibiting effects would benefit from taking and staying 
on lower agomelatine doses (ie, 25 mg/day). By contrast, 
patients who smoke and those taking drugs that induce 
CYP-1A2 enzyme activity (eg, the proton pump inhibitor 
drug omeprazole) may be more likely to require doses of 
50 mg/day or possibly even higher doses (although this has 
not been evaluated clinically).
In patients with normal hepatic function, impaired renal 
function may result in higher concentrations of agomelatine 
metabolites rather than the parent drug. Patients with renal 
impairment do not require any special laboratory monitoring 
with the use of agomelatine, but they should still be monitored 
for increased adverse effects.
The treatment of depression is provided in 3 phases, and 
each phase has different therapeutic goals.71 The acute phase, 
which typically lasts 6 to 12 weeks, refers to the initial treat-
ment period, where the treatment is administered with the 
goal of achieving full symptom remission. The continuation 
phase, typically 4 to 9 months, follows acute phase treatment 
and is recommended for all patients. The goal of continuation 
phase treatment is to prevent early relapse and to allow further 
symptomatic and psychosocial functional improvement. The 
goal of maintenance phase treatment is to prevent further 
recurrences of depression among patients who have a high 
risk of developing depression again. Such risk factors include 
three or more previous episodes of major depression, chronic 
depression, residual or persistent depressive symptoms 
despite adequate treatment, and severe or disabling episodes 
of depression. The length of maintenance treatment will 
depend on the number of risk factors, and may range from one 
year or more or even to life-long treatment. Compared to other 
antidepressant drugs, agomelatine has not been systematically 
studied beyond continuation phase treatment.
Given the availability of a wide variety of potentially 
effective therapies, how does one choose among these 
treatments? Because of the expected delay in onset of anti-
depressant effect, adherence to treatment is very important. 
Adherence also is obviously important for longer-term 
continuation and maintenance treatment. The initial selec-
tion of medication, as well as adherence to treatment, are 
influenced by such factors as cost and availability, patient 
preference, past treatment history, family treatment history, 
clinical symptoms, expected side effect profile and safety, and 
the need for medical/laboratory monitoring.72 Comparative 
data on the relative efficacy, tolerability, safety, and accept-
ability of the antidepressant drug treatment options would 
be helpful, but is often lacking.73,74
As a new product, relatively less is known about many of 
these issues with agomelatine vis-à-vis other antidepressant 
drugs. Given the current status of agomelatine, what areas 
deserve further study? Because the oral bioavailability of 
agomelatine is very low at recommended doses, there is a 
critical need to investigate its pharmacokinetics, efficacy, 
tolerability, and safety in patients taking doses higher than 
50 mg/day. In an early 4-week phase II safety and efficacy 
pilot study, 28 hospitalized depressed patients (18–65 years 
old) were randomized to receive double-blind treatment at one 
of two doses of agomelatine (5 mg/day versus 100 mg/day).25,75 
There was no placebo control and the MADRS was the 
primary outcome measure. MADRS scores decreased signifi-
cantly in both groups and there was no significant difference 
between groups. One subject in each group dropped out due 
to adverse events and two dropped out in each group due to 
lack of efficacy. Acceptability of both doses was reported 
to be good, but there were slightly more TEAEs and severe 
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TEAEs in the 100 mg group. There were no observed adverse 
cardiovascular effects or abnormal laboratory studies in either 
group. Future clinical studies should investigate the efficacy, 
tolerability, and safety of agomelatine in the 50 to 100 mg/day 
dose range.
The efficacy, tolerability, and safety of agomelatine 
also should be further investigated in “real world” patient 
populations, in pediatric and in geriatric patients, and in main-
tenance therapy studies extending for more than 6 months. 
Information is needed about the effects of agomelatine 
during pregnancy and breast feeding.76,77 The relative effec-
tiveness of agomelatine also should be evaluated in com-
parison with SSRIs, SNRIs, and other antidepressant drugs 
using their full dose range, rather than minimally effective 
doses.78 Given agomelatine’s pharmacology and clinical 
profile, comparisons with the antidepressant drugs bupro-
pion, nefazodone, and mirtazapine would be of particular 
interest. Bupropion is a nonserotonergic drug that has 
relatively benign sexual, gastrointestinal, and weight effects. 
Nefazodone is a 5HT2A receptor antagonist, with favorable 
sleep, anxiety, sexual, gastrointestinal, and weight effects. 
Mirtazapine has a complicated pharmacology that includes 
5HT2A, 5HT2C, and 5HT3 receptor antagonism, and it has 
favorable anxiety, sleep, gastrointestinal, and sexual effects, 
but it is prone to sedation and weight gain. Trazodone also 
has 5HT2A and 5HT2C receptor antagonist effects. However, 
it is most commonly used in low doses as a hypnotic, and 
is rarely used as an antidepressant because of sedation and 
the risk of priapism (in men) when used at higher antide-
pressant therapeutic doses. The SSRI and SNRI drugs have 
been extensively investigated, approved, and marketed for 
the treatment of various anxiety disorders. Except for the 
recently published study of generalized anxiety disorder, 
agomelatine has not been investigated for the treatment of 
various anxiety disorders.68
The combined action at MT1, MT2, and 5HT-2C 
receptors, which may resynchronize disturbed circadian 
rhythms and abnormal sleep patterns, suggest that agomela-
tine might be particularly effective for the treatment of 
seasonal affective disorder as well as bipolar depression.79,80 
Preliminary open-label studies in these patient populations 
have suggested some benefit81,82 and further studies in these 
patient populations is clearly warranted.
For patients not responding adequately to an initial anti-
depressant medication, or for patients who cannot tolerate the 
medication, the two main treatment approaches are switching 
or augmentation.83 The unique pharmacology of agomelatine 
suggests a potential role not only as an appropriate switch 
agent for medication intolerance or nonresponse, but also as 
an augmentation agent that could be used in combination with 
other antidepressant drugs. Combining antidepressant drugs 
for treatment nonresponders is commonly done in clinical 
practice. One rationale for this strategy is that antidepressant 
drugs from different classes have distinct pharmacological 
properties. These distinct properties may complement each 
other when used in combination, potentially resulting in 
additive or synergistic neurobiological and clinical effects. 
For example, mirtazapine and some second generation 
antipsychotic drugs have each been shown to be effective 
as add-on therapies for treatment resistant depression.38,84 
Based on the same rationale, combining agomelatine’s 
particular pharmacology with other antidepressant drugs, 
especially SSRI and SNRI drugs, could be done to achieve 
a synergistic antidepressant effect. Similarly, the 5HT2C 
receptor antagonist effects of agomelatine might justify 
its use in combination with SSRI or SNRI drugs as a way 
to counter their serotonin-related adverse effects, such as 
sexual dysfunction, gastrointestinal complaints, or insomnia. 
Controlled studies investigating the use of agomelatine as 
a switch agent or in combination with other antidepressant 
drugs for these clinical purposes are warranted.
With the advent of newer generation antidepressant drugs 
such as agomelatine, are patients with depression better off 
than they were 10 years ago? Depression can be a devastat-
ing and sometimes difficult-to-treat illness, and it is always 
good to have alternative treatment options. The choice of 
drug treatment for an individual patient should be based as 
much as possible on the best unbiased clinical and scientific 
information available. Agomelatine does not have clinically 
significant advantages compared to other antidepressant 
drugs, and it has certain limitations and disadvantages. 
Because of its unique pharmacology and relatively benign 
tolerability profile, however, it may be a useful alternative 
for patients who do not respond to or cannot tolerate other 
antidepressant drugs.
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